Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria

Louis B. Rice, MD
Louis Stokes Cleveland VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH

Correspondence: Louis B. Rice, MD, Medical Service, Louis Stokes Cleveland VA Medical Center, 10701 East Blvd., Cleveland, OH 44106; louis.rice@med.va.gov

Dr. Rice reported that he has received consulting/advisory fees from Wyeth Pharmaceuticals, Elan Corp., Merck & Co., Novexel, and Johnson & Johnson and has received honoraria from Wyeth and Elan for speaking or writing.

The author reported that he prepared this article without assistance from any medical education company.

Louis B. Rice, MD
Louis Stokes Cleveland VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH

Correspondence: Louis B. Rice, MD, Medical Service, Louis Stokes Cleveland VA Medical Center, 10701 East Blvd., Cleveland, OH 44106; louis.rice@med.va.gov

Dr. Rice reported that he has received consulting/advisory fees from Wyeth Pharmaceuticals, Elan Corp., Merck & Co., Novexel, and Johnson & Johnson and has received honoraria from Wyeth and Elan for speaking or writing.

The author reported that he prepared this article without assistance from any medical education company.

Louis B. Rice, MD
Louis Stokes Cleveland VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH

Correspondence: Louis B. Rice, MD, Medical Service, Louis Stokes Cleveland VA Medical Center, 10701 East Blvd., Cleveland, OH 44106; louis.rice@med.va.gov

Dr. Rice reported that he has received consulting/advisory fees from Wyeth Pharmaceuticals, Elan Corp., Merck & Co., Novexel, and Johnson & Johnson and has received honoraria from Wyeth and Elan for speaking or writing.

The author reported that he prepared this article without assistance from any medical education company.